Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates

Clin Genitourin Cancer. 2016 Apr;14(2):e187-93. doi: 10.1016/j.clgc.2015.11.004. Epub 2015 Nov 11.
No abstract available

Keywords: Cell signaling pathways; Morphoproteomics; Refractory; Resistance; Resistant.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Bevacizumab / administration & dosage
  • Bevacizumab / pharmacology
  • Capecitabine / administration & dosage
  • Capecitabine / pharmacology
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / metabolism
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / metabolism
  • Male
  • Mechanistic Target of Rapamycin Complex 2
  • Middle Aged
  • Multiprotein Complexes / genetics
  • Multiprotein Complexes / metabolism
  • Neoplasm Metastasis
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / pharmacology
  • Oxaliplatin
  • Proteomics / methods*
  • Sequence Analysis, DNA / methods*
  • Signal Transduction
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism
  • Treatment Outcome

Substances

  • Multiprotein Complexes
  • Organoplatinum Compounds
  • Oxaliplatin
  • Bevacizumab
  • Capecitabine
  • Mechanistic Target of Rapamycin Complex 2
  • TOR Serine-Threonine Kinases